Medicure completes enrollment in MEND-PNPO Phase 3 trial of MC-1
Trial reached its target of 10 patients; participants are moving through treatment and follow-up.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Medicure Inc. (MPH) Completes Enrollment in Phase 3 PNPO Trial
Medicure completed enrollment of 10 patients in its MEND-PNPO Phase 3 study of MC-1 for PNPO deficiency. The program has FDA Orphan, Rare Pediatric Disease, and Fast Track designations; MC-1 is not FDA-approved.Material DetailsContext by AI AnalystThis is an execution milestone in an ultra-rare epi…